Dosage of Kidonax in details
Recommended Dosage And Important Administration Instructions
Important Administration Instructions For Pediatric Patients 11 Years Of Age Or Younger
Kidonax tablets should not be administered to pediatric patients 11 years of age or younger because a single tablet contains a greater amount of Kidonax than the recommended dosing in this pediatric age group.
Table 1: Recommended Dosage
| Age | Dosage | Duration |
| 1-3 years | 5 mL of Kidonax for Oral Suspension (100 mg Kidonax) taken orally every 12 hours with food | 3 days |
| 4-11 years | 10 mL of Kidonax for Oral Suspension (200 mg Kidonax) taken orally every 12 hours with food | |
| 12 years and older | One Kidonax Tablet (500 mg Kidonax) taken orally every 12 hours with food or 25 mL of Kidonax for Oral Suspension (500 mg Kidonax) taken orally every 12 hours with food |
Directions For Mixing Kidonax For
Oral Suspension
Reconstitute Kidonax for
Oral Suspension as follows:
- Measure 48 mL of water for preparation of the 100 mg/5 mL suspension.
- Tap bottle until all powder flows freely.
- Add approximately one-half of the 48 mL of water required for reconstitution and shake vigorously to suspend powder.
- Add remainder of water and again shake vigorously.
Keep container tightly closed, and shake the suspension well before each administration. The reconstituted suspension may be stored for 7 days at room temperature, after which any unused portion must be discarded.
How supplied
Dosage Forms And Strengths
Kidonax Tablets (500 mg)
Round, yellow, film-coated tablets debossed with Kidonax on one side and 500 on the other side. Each tablet contains 500 mg of Kidonax.
Kidonax For
Oral Suspension (100 mg/5 mL)
Pink-colored powder formulation that, when reconstituted as directed, contains 100 mg Kidonax/5 mL. The reconstituted suspension has a pink color and strawberry flavor.
Storage And Handling
Kidonax Tablets (500 mg)
Kidonax tablets are round, yellow, film-coated tablets debossed with Kidonax on one side and 500 on the other side. Each tablet contains 500 mg of Kidonax. The tablets are packaged in HDPE bottles of 12 and 30 tablets.
Bottles of 12 tablets NDC 67546-111-14
Bottles of 30 tablets NDC 67546-111-12
Store the tablets at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F).
Kidonax For
Oral Suspension (100 mg/5 mL)
Kidonax for oral suspension is a pink-colored powder formulation that, when reconstituted as directed, contains 100 mg Kidonax/5 mL. The reconstituted suspension has a pink color and strawberry flavor. Kidonax for oral suspension is available as:
Bottles of 60 mL NDC 27437-106-01
Store the unsuspended powder, at 25°C (77°F); excursions permitted to 15°C-30°C (59°F -86°F).
The reconstituted suspension may be stored for 7 days at room temperature, after which any unused portion must be discarded
Romark, L.C. 3000 Bayport Drive, Suite 200, Tampa, FL 33607 Telephone: 813-282-8544, Fax: 813-282-1162 E-mail: customer.service@romark.com Web site: www.romark.com. Revised: July 2016
What other drugs will affect Kidonax?
Many drugs may affect the way that Kidonax is metabolized ("broken down") in the body, leading to higher or lower than expected levels of the medication in the blood. Talk to your doctor before taking any other medicines during treatment with Kidonax.
Talk to your doctor before taking other prescription or over-the-counter medications including vitamins, minerals, and herbal products during treatment with Kidonax.
Kidonax interactions
Tizoxanide is highly bound to plasma protein (>99.9%). Therefore, caution should be used when administering Kidonax concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin). In vitro metabolism studies have demonstrated that tizoxanide has no significant inhibitory effect on cytochrome P450 enzymes. Although no drug-drug interaction studies have been conducted in vivo, it is expected that no significant interaction would occur when Kidonax is co-administered with drugs that either are metabolized by or inhibit cytochrome P450 enzymes.
References
- DailyMed. "NITAZOXANIDE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- FDA/SPL Indexing Data. "SOA12P041N: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
- MeSH. "Antiparasitic Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Kidonax are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Kidonax. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported frequency of use
No survey data has been collected yetConsumer reported doses
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
